KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Enterprise Value (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Enterprise Value data on record, last reported at -$270.2 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 10.52% year-over-year to -$270.2 million; the TTM value through Sep 2025 reached -$270.2 million, down 10.52%, while the annual FY2024 figure was -$255.2 million, 15.94% up from the prior year.
  • Enterprise Value reached -$270.2 million in Q3 2025 per NKTR's latest filing, down from -$175.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$175.9 million in Q2 2025 and bottomed at -$1.0 billion in Q1 2021.
  • Average Enterprise Value over 5 years is -$489.3 million, with a median of -$409.4 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: surged 40.68% in 2022, then decreased 10.52% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$734.0 million in 2021, then surged by 31.2% to -$505.0 million in 2022, then surged by 39.88% to -$303.6 million in 2023, then grew by 15.94% to -$255.2 million in 2024, then fell by 5.87% to -$270.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$270.2 million in Q3 2025, -$175.9 million in Q2 2025, and -$218.6 million in Q1 2025.